To access this content, you must purchase 1 Year Health News Illinois Subscription or 1 Year Group Subscription - Up to 5 Users, or log in if you are a member.
Provider groups renew push for legislation to ensure access to 340B Program drugs
Pfizer And AstraZeneca's Billion Dollar Battle...Boxes containing various pharmaceutical products are seen on display in the pharmacy department of a drugstore in London, U.K., on Friday, May 2, 2014. AstraZeneca Plc rejected Pfizer Inc.'s sweetened takeover proposal, saying the 63.1 billion-pound ($106.5 billion) offer fails to recognize the value of the promising experimental medicines under development by the U.K.'s second-biggest drugmaker. Photographer: Chris Ratcliffe/Bloomberg
With several weeks left in the spring legislative session, several healthcare associations are again calling on lawmakers to consider legislation that would prohibit pharmaceutical manufacturers from interfering with the ability of providers to receive prescription drugs if contracted with the 340B program, which provides discounted drugs to safety-net providers.